Shijiyao Group(02005) Mengumumkan kinerja tahunan, laba bersih sekitar 471 juta HKD, turun 55,6% dibandingkan tahun sebelumnya. Dividen akhir 0,03 HKD.

Shi Si Pharmaceutical Group (02005) released its full-year financial results for the fiscal year ending December 31, 2025. In 2025, under the multiple pressures of demand contraction, policy deepening, and intensified industry competition, the group’s main economic indicators experienced unprecedented downward pressure in recent years and went through an extremely severe test. Facing difficulties, the group actively converted pressure into motivation, adopting an innovative, pragmatic, and proactive approach to push the enterprise forward in breaking through.

For the full year 2025, sales revenue amounted to approximately RMB 3.812 billion, a year-on-year decrease of 27.6%; in Hong Kong dollars, annual sales revenue was approximately HKD 4.165 billion, a year-on-year decrease of 27.8%; the gross margin for the same period was approximately 41.6%, down 8.8 percentage points year-on-year; net profit reached approximately HKD 471 million, a year-on-year decrease of 55.6%.

The Board of Directors resolved to distribute a final dividend of HKD 0.03 per share on June 4, 2026 to shareholders whose names appear in the company’s shareholder register on May 21, 2026, with total annual dividend distribution of HKD 0.08 per share, a year-on-year decrease of 54.3%.

Throughout the year, the group continuously improved the market accessibility of its products. In 2025, the group overcame adverse factors and made solid progress in effectively connecting new product approvals with market entry in various regions, seizing opportunities to participate in national centralized procurement, follow-up procurement, inter-provincial alliance procurement, and various local pharmaceutical tender activities. The group completed market entry for 42 generic names covering 52 product specifications. Meanwhile, the group participated in national centralized procurement follow-ups, inter-provincial and local joint procurement, and medical institution pharmaceutical tender activities over a thousand times. Notably, the group performed outstandingly and had clear bidding advantages in the 11th national centralized procurement, Beijing-Tianjin-Hebei 3+N alliance volume-based procurement follow-ups, Sichuan sodium chloride and other large-volume injection volume-based procurement alliances, environmental phosphoadenosine and other 66 chemical pharmaceutical inter-provincial alliance volume-based joint procurement, Guangdong alliance diclofenac and other pharmaceutical centralized procurement follow-ups, and Guangdong alliance common chronic disease alliance follow-ups, further consolidating the market foundation in key regions and creating conditions for enhancing product accessibility. Additionally, the group’s national medical insurance catalog products continue to diversify. The 2025 national new version of the medical insurance catalog added calcium gluconate sodium chloride injection, and the group currently has 201 products in the national medical insurance catalog.

Abundant information and accurate insights are available on the Sina Finance APP